Rilotumumab, a mab against human Hepatocyte growth factor for the treatment of cancer

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Tyrosine kinase receptors and their ligands have become appealing candidates as molecular therapeutic agents for the treatment of cancer. Hepatocyte growth factor (HGF) and its receptor, mesenchymal-epithelial transition factor (c-Met), play a role in many human tumors, promoting cell proliferation and invasion, as well as resistance to apoptosis. Rilotumumab, being developed by Amgen Inc, is a humanized mAb directed against HGF, and is thus able to interfere with the interaction between HGF and c-Met to prevent c-Met activation. In preclinical studies, rilotumumab effectively blocked c-Met phosphorylation, inhibiting c-Met-activated downstream signaling pathways. In phase I clinical trials, rilotumumab was well tolerated at doses up to 20 mg/kg every 2 weeks. Data from preclinical studies and a phase Ib trial demonstrated that rilotumumab had an additive effect when combined with chemotherapeutic agents, leading to the initiation of several phase II trials that are enrolling patients with different tumor types to assess combinations of rilotumumab with chemotherapeutic regimens, as well as with other mAbs. Which tumor types might beneft most from treatment with rilotumumab remains to be determined, and the identifcation of candidate patients will be a critical issue for the further development of this drug.

Original languageEnglish
Pages (from-to)448-455
Number of pages8
JournalCurrent Opinion in Molecular Therapeutics
Volume11
Issue number4
Publication statusPublished - Aug 2009

Fingerprint

Neoplasms
Hepatocyte Growth Factor
Therapeutics
Proto-Oncogene Proteins c-met
Clinical Trials, Phase I
Epithelial-Mesenchymal Transition
Receptor Protein-Tyrosine Kinases
human HGF protein
rilotumumab
Phosphorylation
Cell Proliferation
Apoptosis
Ligands
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)
  • Drug Discovery
  • Pharmacology

Cite this

Rilotumumab, a mab against human Hepatocyte growth factor for the treatment of cancer. / Giordano, Silvia.

In: Current Opinion in Molecular Therapeutics, Vol. 11, No. 4, 08.2009, p. 448-455.

Research output: Contribution to journalArticle

@article{2a1e9a84afe74164b18fabf316a8b1db,
title = "Rilotumumab, a mab against human Hepatocyte growth factor for the treatment of cancer",
abstract = "Tyrosine kinase receptors and their ligands have become appealing candidates as molecular therapeutic agents for the treatment of cancer. Hepatocyte growth factor (HGF) and its receptor, mesenchymal-epithelial transition factor (c-Met), play a role in many human tumors, promoting cell proliferation and invasion, as well as resistance to apoptosis. Rilotumumab, being developed by Amgen Inc, is a humanized mAb directed against HGF, and is thus able to interfere with the interaction between HGF and c-Met to prevent c-Met activation. In preclinical studies, rilotumumab effectively blocked c-Met phosphorylation, inhibiting c-Met-activated downstream signaling pathways. In phase I clinical trials, rilotumumab was well tolerated at doses up to 20 mg/kg every 2 weeks. Data from preclinical studies and a phase Ib trial demonstrated that rilotumumab had an additive effect when combined with chemotherapeutic agents, leading to the initiation of several phase II trials that are enrolling patients with different tumor types to assess combinations of rilotumumab with chemotherapeutic regimens, as well as with other mAbs. Which tumor types might beneft most from treatment with rilotumumab remains to be determined, and the identifcation of candidate patients will be a critical issue for the further development of this drug.",
author = "Silvia Giordano",
year = "2009",
month = "8",
language = "English",
volume = "11",
pages = "448--455",
journal = "Current Opinion in Molecular Therapeutics",
issn = "1464-8431",
publisher = "Current Drugs Ltd.",
number = "4",

}

TY - JOUR

T1 - Rilotumumab, a mab against human Hepatocyte growth factor for the treatment of cancer

AU - Giordano, Silvia

PY - 2009/8

Y1 - 2009/8

N2 - Tyrosine kinase receptors and their ligands have become appealing candidates as molecular therapeutic agents for the treatment of cancer. Hepatocyte growth factor (HGF) and its receptor, mesenchymal-epithelial transition factor (c-Met), play a role in many human tumors, promoting cell proliferation and invasion, as well as resistance to apoptosis. Rilotumumab, being developed by Amgen Inc, is a humanized mAb directed against HGF, and is thus able to interfere with the interaction between HGF and c-Met to prevent c-Met activation. In preclinical studies, rilotumumab effectively blocked c-Met phosphorylation, inhibiting c-Met-activated downstream signaling pathways. In phase I clinical trials, rilotumumab was well tolerated at doses up to 20 mg/kg every 2 weeks. Data from preclinical studies and a phase Ib trial demonstrated that rilotumumab had an additive effect when combined with chemotherapeutic agents, leading to the initiation of several phase II trials that are enrolling patients with different tumor types to assess combinations of rilotumumab with chemotherapeutic regimens, as well as with other mAbs. Which tumor types might beneft most from treatment with rilotumumab remains to be determined, and the identifcation of candidate patients will be a critical issue for the further development of this drug.

AB - Tyrosine kinase receptors and their ligands have become appealing candidates as molecular therapeutic agents for the treatment of cancer. Hepatocyte growth factor (HGF) and its receptor, mesenchymal-epithelial transition factor (c-Met), play a role in many human tumors, promoting cell proliferation and invasion, as well as resistance to apoptosis. Rilotumumab, being developed by Amgen Inc, is a humanized mAb directed against HGF, and is thus able to interfere with the interaction between HGF and c-Met to prevent c-Met activation. In preclinical studies, rilotumumab effectively blocked c-Met phosphorylation, inhibiting c-Met-activated downstream signaling pathways. In phase I clinical trials, rilotumumab was well tolerated at doses up to 20 mg/kg every 2 weeks. Data from preclinical studies and a phase Ib trial demonstrated that rilotumumab had an additive effect when combined with chemotherapeutic agents, leading to the initiation of several phase II trials that are enrolling patients with different tumor types to assess combinations of rilotumumab with chemotherapeutic regimens, as well as with other mAbs. Which tumor types might beneft most from treatment with rilotumumab remains to be determined, and the identifcation of candidate patients will be a critical issue for the further development of this drug.

UR - http://www.scopus.com/inward/record.url?scp=68649091709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68649091709&partnerID=8YFLogxK

M3 - Article

C2 - 19649990

AN - SCOPUS:68649091709

VL - 11

SP - 448

EP - 455

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

SN - 1464-8431

IS - 4

ER -